|
|
| | DCZ0415 Basic information |
| Product Name: | DCZ0415 | | Synonyms: | DCZ0415;DCZ0415,DCZ 0415,Apoptosis,inhibit,nonhomologous,Nuclear factor-κB,TRIP13,Inhibitor,joining,DCZ-0415,end,drug-resistant,myeloma,repair,anti-myeloma,Nuclear factor-kappaB,NF-κB;4,6-Ethenocycloprop[f]isoindole-1,3(2H,3aH)-dione, 4,4a,5,5a,6,6a-hexahydro-2-[4-(4-pyridinylmethyl)phenyl]- | | CAS: | 2242470-43-3 | | MF: | C23H20N2O2 | | MW: | 356.42 | | EINECS: | | | Product Categories: | | | Mol File: | 2242470-43-3.mol |  |
| | DCZ0415 Chemical Properties |
| Boiling point | 624.2±55.0 °C(Predicted) | | density | 1.319±0.06 g/cm3(Predicted) | | solubility | DMSO:62.5(Max Conc. mg/mL);175.35(Max Conc. mM) | | form | Solid | | pka | 5.80±0.10(Predicted) | | color | Off-white to yellow |
| | DCZ0415 Usage And Synthesis |
| Description | DCZ0415 is a novel inhibitor of TRIP13, suppressing multiple myeloma progression. | | target | DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. |
| | DCZ0415 Preparation Products And Raw materials |
|